BioSpace News Archive

Soterix Medical Inc. (SMI), a global leader in non-invasive stimulation and synergistic brain monitoring technologies, announced today that patient recruitment for its treatment resistant depression trial funded by National Institute of Health has begun in New York City.

Citius Pharmaceuticals Inc. announced the closing of its previously announced registered direct offering with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per share and accompanying warrant.

Enabled by a national network of trusted, long-standing relationships with medical professionals, Quest HealthConnect provides a personalized approach, often at members’ homes, through an on-site Health Risk Assessment.

The National Academy of Sciences has announced that Claire M. Fraser, PhD, the Dean E. Albert Reece Endowed Professor in the Department of Medicine at the University of Maryland School of Medicine, and the Founding Director of the Institute for Genome Sciences, has been elected as a new member of the prestigious academy.

MCRA, LLC is pleased to announce its role in assisting Noctrix Health obtain marketing authorization via a De Novo Request from the U.S. Food and Drug Administration (FDA) for the NTX100 Tonic Motor Activation (NTX100 TOMAC) System.

Because millions of people experience fatal venous and arterial thrombosis – blood clots – per year and those with COVID-19 are at higher risk, researchers at The Feinstein Institutes for Medical Research helped to design and implement an entirely virtual, outpatient, cloud-based clinical trial to understand the efficacy of a common prophylactic medication: rivaroxaban.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the first quarter ending March 31, 2023.

BioAtla, Inc. announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.